Your AI-Designed Antibody Binds EGFR. Does It Bind at the Wrong pH?
Imagine your model gives you two antibodies. Both bind the human epidermal growth factor receptor (EGFR) about equally well at pH 6.5. You repeat the experiment at pH 7.4. One still binds strongly. The other gives you a curve you can barely distinguish from background. For this particular design brief, I’d take a closer look at the antibody with the flat curve. The Poreva Open EGFR challenge ,…
An antibody engineered to target human epidermal growth factor receptor (EGFR) displays differing binding affinities at varying pH levels, a discovery that could influence its viability in medical applications. Two antibodies emerged in the study: G532 and its control. The engineered antibody, G532, exhibited weaker binding at a neutral pH of 7.4, while the control showed stronger binding.
The study was prompted by the Poreva Open EGFR challenge, which demanded antibodies that bind to EGFR at a pH of 6.5 and show no detectable binding at pH 7.4. This pH selectivity carries a scoring weight of 30%, making it a critical factor in the design's success. The researchers recommend further investigation into antibodies that exhibit weaker binding at neutral pH, as they could potentially preferentially bind to EGFR at the more acidic conditions often found in tumor tissues.
The findings underscore the importance of considering pH in antibody design, as it could significantly impact the antibody's effectiveness in targeting specific cells.
Rewritten by urgent.news; may contain errors — check the original.